Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- PII Data Updated for Sumitomo Dainippon’s Napabucasin
June 6, 2017
- Details Revealed for Lenvima’s Non-Inferiority Study vs Nexavar in 1st Line HCC
June 6, 2017
- Linzess Most Heavily Promoted for GPs in Launch Month of March: Anterio
June 6, 2017
- Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
- Astellas, Kyoto Univ. Launch New 3-Year Joint Project
June 5, 2017
- AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
- Sugino Appointed President of Amgen Astellas
June 2, 2017
- New Ninlaro Production Facility in Ireland Breaks Ground
June 2, 2017
- Eisai, Broad Institute Ink New Deal on Malaria Medicine
June 2, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- PeptiDream, Shionogi, Sekisui Chemical to Form CMO for Specialty Peptide
June 2, 2017
- Once-Every-4-Week Administration of Praluent Meets Primary Endpoint in PIII Study in Japanese Patients: Sanofi
June 2, 2017
- FY2016 Earnings Roundup - 5: Drug Makers Anticipate Nearly Flat Growth in FY2017; Mid-Term Outlook Unclear
June 2, 2017
- Ono Licenses MEK Inhibitor, BRAF Inhibitor from Array Biopharma
June 1, 2017
- NBI, Kobe Univ. Tie Up to Develop Novel Treatments for Insulin-Resistant Disorders
June 1, 2017
- Daiichi Sankyo to Commercialize Opioid Analgesic in US, Eying Launch during FY2017
June 1, 2017
- FY2016 Earnings Roundup - 4: Average Productivity per Sales Rep Up Only 14 Million Yen in 6 Years
June 1, 2017
- FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
- FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
- Sunovion’s COPD Med Slapped with FDA Complete Response Letter
May 30, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…